Randomized, double-blind, placebo-controlled, parallel-group study of the safety and efficacy of imeglimin or placebo add-on therapy in type 2 diabetic subjects not adequately controlled by sitagliptin monotherapy
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2014
At a glance
- Drugs Imeglimin (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Poxel
- 10 Apr 2014 Results published in the Diabetes Care.
- 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 05 Nov 2012 Status changed from recruiting to completed based on a Poxel media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History